Solid Tumor Cancer Treatment Market (By Type: Sarcomas, Carcinomas; By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy; By Route of Administration: Oral, Parenteral, Others; By End-Users: Hospitals, Research Institutes, Homecare) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Solid Tumor Cancer Treatment Market
5.1. COVID-19 Landscape: Solid Tumor Cancer Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Solid Tumor Cancer Treatment Market, By Type
8.1. Solid Tumor Cancer Treatment Market, by Type, 2022-2032
8.1.1. Sarcomas
8.1.1.1. Market Revenue and Forecast (2022-2032)
8.1.2. Carcinomas
8.1.2.1. Market Revenue and Forecast (2022-2032)
Chapter 9. Global Solid Tumor Cancer Treatment Market, By Treatment
9.1. Solid Tumor Cancer Treatment Market, by Treatment, 2022-2032
9.1.1. Chemotherapy
9.1.1.1. Market Revenue and Forecast (2022-2032)
9.1.2. Immunotherapy
9.1.2.1. Market Revenue and Forecast (2022-2032)
9.1.3. Targeted Therapy
9.1.3.1. Market Revenue and Forecast (2022-2032)
Chapter 10. Global Solid Tumor Cancer Treatment Market, By Route of Administration
10.1. Solid Tumor Cancer Treatment Market, by Route of Administration, 2022-2032
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2022-2032)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2022-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2022-2032)
Chapter 11. Global Solid Tumor Cancer Treatment Market, By End-Users
11.1. Solid Tumor Cancer Treatment Market, by End-Users, 2022-2032
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2022-2032)
11.1.2. Research Institutes
11.1.2.1. Market Revenue and Forecast (2022-2032)
11.1.3. Homecare
11.1.3.1. Market Revenue and Forecast (2022-2032)
Chapter 12. Global Solid Tumor Cancer Treatment Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2022-2032)
12.1.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.1.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.1.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type (2022-2032)
12.1.5.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.1.5.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type (2022-2032)
12.1.6.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.1.6.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2022-2032)
12.2.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.2.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.2.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type (2022-2032)
12.2.5.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.2.5.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type (2022-2032)
12.2.6.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.2.6.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type (2022-2032)
12.2.7.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.2.7.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type (2022-2032)
12.2.8.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.2.8.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2022-2032)
12.3.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.3.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.3.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type (2022-2032)
12.3.5.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.3.5.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type (2022-2032)
12.3.6.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.3.6.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type (2022-2032)
12.3.7.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.3.7.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type (2022-2032)
12.3.8.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.3.8.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2022-2032)
12.4.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.4.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.4.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type (2022-2032)
12.4.5.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.4.5.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type (2022-2032)
12.4.6.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.4.6.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type (2022-2032)
12.4.7.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.4.7.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type (2022-2032)
12.4.8.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.4.8.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2022-2032)
12.5.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.5.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.5.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type (2022-2032)
12.5.5.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.5.5.4. Market Revenue and Forecast, by End-Users (2022-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type (2022-2032)
12.5.6.2. Market Revenue and Forecast, by Treatment (2022-2032)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.5.6.4. Market Revenue and Forecast, by End-Users (2022-2032)
Chapter 13. Company Profiles
13.1. F.Hoffman- La Roche Ltd.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Mylan N.V.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Sanofi
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Pfizer
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Merck & Co
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Allergan
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AstraZeneca
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Bayer AG
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Lupin
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample